Literature DB >> 31361930

Urticarial rash, fever, and arthritis: A case of refractory Adult-onset Still's disease with good response to tocilizumab.

Bartlomiej Wawrzycki1, Dorota Krasowska1, Aldona Pietrzak1, Ewa Wielosz2, Maria Majdan2, Torello Lotti3.   

Abstract

Adult-onset Still's disease (AOSD) is a rare, systemic inflammatory disorder of not completely understood etiology. Aberrant activation of the innate immune system and overproduction of several pro-inflammatory mediators are considered a critical component in disease pathogenesis. AOSD still poses a challenge due to the broad range of differential diagnoses and no specific biomarkers. Four cardinal symptoms are quotidian spiking fever, joint involvement, evanescent salmon pink-rash rash, and leukocytosis with neutrophilia. We present a case of a 61-year-old female with a recurrent urticarial rash accompanied by attacks of high fever, tender joints, sore throat, enlarged liver, elevated inflammatory reactants, and hyperferritinemia. After an extensive workup, the patient fulfilled the criteria of AOSD. She was refractory to the glucocorticosteroids and disease-modifying anti-rheumatic drugs (DMARDs). Finally, after several unsuccessful attempts to achieve disease control with traditional DMAR's administration of Tocilizumab (TCZ), a humanized anti-IL-6 receptor antagonist resulted in substantial disease improvement. Since skin manifestations are a common feature of AOSD, it should be among differential diagnoses in patients with skin lesions and constitutional symptoms. Biologic agents represent a significant therapeutic advance in patients with AOSD refractory to conventional therapy.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Adult-onset Still's disease (AOSD); anti-IL-6; atypical persistent skin eruptions (APSEs); evanescent skin eruption (ESE); multigenic autoinflammatory disease; tocilizumab (TCZ)

Mesh:

Substances:

Year:  2019        PMID: 31361930     DOI: 10.1111/dth.13041

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  2 in total

1.  Extranodal localization of non-Hodgkin's lymphoma in systemic sclerosis: A diagnostic challenge and review of the literature.

Authors:  Giorgio Galoppini; Beatrice Maranini; Giovanni Ciancio; Melissa Padovan; Gian Luca Casoni; Francesco Cavazzini; Roberta Gafà; Giovanni Lanza; Marcello Govoni
Journal:  J Scleroderma Relat Disord       Date:  2022-04-10

Review 2.  Tocilizumab therapy for persistent high-grade fever in systemic lupus erythematosus: two cases and a literature review.

Authors:  Ma Chaoyi; Bikash Shrestha; Li Hui; Ding Qiujin; Fu Ping
Journal:  J Int Med Res       Date:  2022-03       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.